Drug Research

Could the Senate adopt a "watershed" bill allowing drug price discussions after years of government inaction regarding medication prices in the U.S.? Analysts are busy studying the information at hand to determine how the legislation would impact the leading companies...

According to the US Department of Health and Human Services, booster shots from Moderna and Pfizer that have been upgraded to target Omicron coronavirus subvariants may be made accessible in the early fall, subject to approval by federal health...

Pfizer previously held out hope that Eucrisa would become the trendiest topical treatment for inflammatory skin conditions. However, the ointment never took off because of adverse reactions and funding problems. Arcutis Biotherapeutics, a young biotech company, is now introducing...

The use of excessively fragile efficacy data and delays in sponsors' presenting living proof from post-approval trials, as well as the approval of some crucial drugs based on preliminary clinical evidence, continue to be controversial issues. Under the programme,...

According to research, the ratio of nicotinic acid (NA) to nicotinamide (NAM) considerably rises when living microorganisms are present inside 24 hours. This ratio can be used as a biomarker to identify microbial contamination in cell therapies at an...

Pfizer is prepared and equipped to continue its pandemic sales supremacy, the company's chief executive said on a July 28 investor call, even if federal contracts for COVID-19 antivirals and vaccines dry up. During the company's second-quarter earnings call, CEO Albert...

People and the industry have learned a lot about pandemic management by living through COVID-19. Governments all throughout the world are placing a greater emphasis on pandemic preparedness. In that respect, GSK is assisting 12 European nations in being ready...